Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 4:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,330 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo saline injection Clear all
Suspended Phase 1 Interventional

Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy

NCT06680479
View directory record Official record
Conditions
HIV-1
Interventions
CH505 TF chTrimer, 3M-052-AF, Aluminum Hydroxide Suspension, Sodium Chloride for Injection
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
24
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 9, 2026, 4:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults

NCT01666652
View directory record Official record
Conditions
Dengue Fever
Interventions
4 µg TDENV-PIV with Alum adjuvant, 1 µg TDENV-PIV with AS03B1 adjuvant, Phosphate buffered saline, 1 µg TDENV-PIV with Alum adjuvant, 1 µg TDENV-PIV with AS01E1 adjuvant
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 39 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Sep 9, 2026, 4:37 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

NCT05831111
View directory record Official record
Conditions
Epstein-Barr Virus Infection
Interventions
mRNA-1195.1, mRNA-1195.2, mRNA-1189, Placebo, mRNA-1195
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
482 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
34
States / cities
Anniston, Alabama • Tucson, Arizona • Huntington Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 9, 2026, 4:37 PM EDT
Recruiting Phase 2 Interventional

IncobotulinumtoxinA for Provoked Vestibulodynia With Overactive Pelvic Floor Muscle Dysfunction

NCT07486830
View directory record Official record
Conditions
Provoked Vestibulodynia
Interventions
Incobotulinum Toxin A, Placebo
Drug
Lead sponsor
Center for Vulvovaginal Disorders
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 9, 2026, 4:37 PM EDT
Terminated Phase 2 Interventional Results available

Incobotulinum Toxin for the Treatment of Trigeminal Neuralgia

NCT02088632
View directory record Official record
Conditions
Trigeminal Neuralgia
Interventions
Incobotulinumtoxina, Placebo Comparator
Biological · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Sep 9, 2026, 4:37 PM EDT
Recruiting Phase 2 Interventional

Effect of Superior Laryngeal Nerve Blocks on Patient Outcomes in Laryngeal Surgery

NCT06734975
View directory record Official record
Conditions
Vocal Cord Disease, Vocal Cord Polyp, Vocal Cord Cyst
Interventions
Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension), Superior laryngeal nerve block - Placebo (saline)
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 9, 2026, 4:37 PM EDT
Terminated Phase 4 Interventional

Pre-operative Enoxaparin in the Surgical Management of Multi-trauma Patients Undergoing Orthopedic Surgical Procedures

NCT05081375
View directory record Official record
Conditions
Venous Thrombosis Deep (Limbs), Surgical Blood Loss
Interventions
Enoxaparin Injectable Product, Sodium chloride
Drug
Lead sponsor
Valleywise Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 9, 2026, 4:37 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

The Role of Platelet Rich Plasma for Erectile Dysfunction

NCT04357353
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Platelet rich plasma, Placebo Sham Injection
Biological · Other
Lead sponsor
University of Nebraska
Other
Eligibility
50 Years to 80 Years · Male only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 9, 2026, 4:37 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of AM3101 to Augment Meniscal Healing

NCT05560477
View directory record Official record
Conditions
Meniscus Tear
Interventions
AM3101, Saline Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 40 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Cincinnati, Ohio • Cleveland, Ohio • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 9, 2026, 4:37 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial of Regadenoson in Sickle Cell Anemia

NCT01788631
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
Regadenoson, Placebo
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
10 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
12
States / cities
Oakland, California • Chicago, Illinois • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Sep 9, 2026, 4:37 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How a New Pneumococcal Vaccine Works in Adults

NCT07086677
View directory record Official record
Conditions
Streptococcus Pneumoniae
Interventions
PG4 vaccine in Buffer 1 with low dose PA-001, PG4 in Buffer 1 with low dose PA-002, PG4 in Buffer 1 with high dose PA-001, PG4 vaccine in Buffer 1 with high dose PA-002, PG4 vaccine in Buffer 2, 20-valent pneumococcal conjugate vaccine, Saline injection
Biological
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 84 Years
Enrollment
380 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
20
States / cities
Lake Forest, California • Rolling Hills Estates, California • Greenacres City, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 9, 2026, 4:37 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Botulinum Toxin Type A for Cold Intolerance Secondary to Digital Amputations and Replantations: A Pilot Study

NCT04917731
View directory record Official record
Conditions
Cold Intolerance
Interventions
Botulinum toxin type A
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Sep 9, 2026, 4:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Trans Sodium Crocetinate (TSC) in Enhancing Tissue Oxygen Levels in Healthy Volunteers

NCT04808622
View directory record Official record
Conditions
Healthy Subjects
Interventions
Trans-Sodium Crocetinate, Placebo
Drug
Lead sponsor
Diffusion Pharmaceuticals Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Sep 9, 2026, 4:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of RNS60 Given by IV to Healthy Subjects

NCT01264783
View directory record Official record
Conditions
Myocardial Infarct
Interventions
RNS60, Placebo
Drug
Lead sponsor
Revalesio Corporation
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 3, 2011 · Synced Sep 9, 2026, 4:37 PM EDT
Completed Phase 2 Interventional

Investigation of Sleep in the Intensive Care Unit

NCT03355053
View directory record Official record
Conditions
Delirium, Sleep
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years and older
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 9, 2026, 4:37 PM EDT
Completed Phase 3 Interventional Results available

A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine

NCT01662492
View directory record Official record
Conditions
Migraine Disorders
Interventions
Botulinum toxin type A Dose 1, Botulinum toxin type A Dose 2, Placebo (Normal Saline)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
12 Years to 17 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
22
States / cities
Phoenix, Arizona • Fullerton, California • Oceanside, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2017 · Synced Sep 9, 2026, 4:37 PM EDT
Withdrawn Phase 4 Interventional

The Effect of Tranexamic Acid on Transfusion Rates in Intertrochanteric Hip Fractures

NCT01940536
View directory record Official record
Conditions
Hip Fracture, Blood Loss
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 9, 2026, 4:37 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients

NCT07219771
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
PTP-01, Placebo control / saline vehicle
Biological · Other
Lead sponsor
Doron Therapeutics Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Birmingham, Alabama • La Mesa, California • West Hills, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 9, 2026, 4:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults

NCT04966871
View directory record Official record
Conditions
Malaria
Interventions
PfSPZ Vaccine, PfSPZ Challenge (7G8) for CHMI, Normal Saline
Biological · Other
Lead sponsor
Sanaria Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 17, 2022 · Synced Sep 9, 2026, 4:37 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

NCT05736107
View directory record Official record
Conditions
Subcutaneous Fat
Interventions
CBL-514 Injection, 0.9% Sodium Chloride
Drug · Other
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years to 64 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Pflugerville, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2024 · Synced Sep 9, 2026, 4:37 PM EDT
Withdrawn Phase 2 Interventional

A Study to Evaluate the Efficacy of Somatropin in the Treatment of Patellar Tendinopathy

NCT02597660
View directory record Official record
Conditions
Tendinopathy
Interventions
Somatropin, Bacteriostatic saline, Progressive exercise program, Patellar tendon biopsy
Drug · Other · Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 9, 2026, 4:37 PM EDT
Completed Phase 2 Interventional Results available

The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose

NCT04977479
View directory record Official record
Conditions
Systemic Allergic Reaction
Interventions
Pfizer-BioNTech COVID-19 Vaccine (Comirnaty), Placebo, Pfizer-BioNTech COVID-19 Vaccine, Bivalent
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 69 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Sep 9, 2026, 4:37 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Single Dose Safety, Tolerability and Pharmacokinetic Study of NCTX in Healthy Volunteers

NCT02063594
View directory record Official record
Conditions
Healthy Volunteers
Interventions
NCTX (PEGylated Liposomal Iodixanol Injection), Saline Placebo
Drug
Lead sponsor
Marval Pharma Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Sep 9, 2026, 4:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluating the Safety and Efficacy of Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load

NCT01933594
View directory record Official record
Conditions
HIV Infections
Interventions
Romidepsin, Placebo for Romidepsin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 9, 2026, 4:37 PM EDT